Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang Y, Heyenbruch D, Bollard CM, Keller MD, Hanley PJ, Lutzko C, Pham G, Davies SM, Rubinstein JD. Khoury R, et al. Among authors: keller md. Am J Transplant. 2024 Apr 19:S1600-6135(24)00280-6. doi: 10.1016/j.ajt.2024.04.009. Online ahead of print. Am J Transplant. 2024. PMID: 38643944
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein JD, Jodele S, Heyenbruch D, Wilhelm J, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Boghdadly ZE, Mims A, Davies SM, Grimley MS, Nelson AS. Rubinstein JD, et al. Transplant Cell Ther. 2022 Feb;28(2):116.e1-116.e7. doi: 10.1016/j.jtct.2021.11.005. Epub 2021 Nov 14. Transplant Cell Ther. 2022. PMID: 34785398 Free article.
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray L, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley MS. Rubinstein JD, et al. Among authors: keller md. Blood Adv. 2022 May 10;6(9):2897-2907. doi: 10.1182/bloodadvances.2021006309. Blood Adv. 2022. PMID: 35108727 Free PMC article. Clinical Trial.
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, Davies SM, Grimley MS, Rubinstein JD. Galletta TJ, et al. Among authors: keller md. Transplant Cell Ther. 2023 May;29(5):305-310. doi: 10.1016/j.jtct.2023.01.027. Epub 2023 Feb 3. Transplant Cell Ther. 2023. PMID: 36736781 Free article.
Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.
Miller HK, Hanley PJ, Lang H, Lazarski CA, Chorvinsky EA, McCormack S, Roesch L, Albihani S, Dean M, Hoq F, Adams RH, Bollard CM, Keller MD. Miller HK, et al. Among authors: keller md. Biol Blood Marrow Transplant. 2018 Sep;24(9):1944-1946. doi: 10.1016/j.bbmt.2018.04.030. Epub 2018 May 9. Biol Blood Marrow Transplant. 2018. PMID: 29753156 Free PMC article.
EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.
Rubinstein JD, Burns K, Absalon M, Lutzko C, Leemhuis T, Chandra S, Hanley PJ, Keller MD, Davies SM, Nelson A, Grimley M. Rubinstein JD, et al. Among authors: keller md. Pediatr Blood Cancer. 2020 Mar;67(3):e28126. doi: 10.1002/pbc.28126. Epub 2019 Dec 18. Pediatr Blood Cancer. 2020. PMID: 31850668
164 results